GLOBIVAC ND UNIQUE VACCINE

Dosage

Children: Refer to specific medications used to treat the particular disease for dosing information.

Adults: Refer to specific medications used to treat the particular disease for dosing information.

Mechanism of action

The mechanism of action varies significantly depending on the specific disease in question. For infectious diseases, pathogens may interact with host cells, leading to inflammation, immune response activation, or tissue damage. Chronic diseases often involve complex interactions between genetic factors, lifestyle choices, and environmental influences. For example, in autoimmune diseases, the immune system mistakenly targets healthy cells, leading to inflammation and tissue destruction.

Pharmacodynamics

Pharmacodynamics of disease involves understanding how the disease state affects physiological functions and the body's response to treatment. In infectious diseases, the presence of pathogens can lead to altered immune responses, while chronic diseases may involve changes in metabolic pathways, hormonal balances, or cellular functions. Medications targeting disease processes aim to restore normal function, alleviate symptoms, or eradicate pathogens.

Pharmacokinetics

Pharmacokinetics is not applicable to the term 'disease' as it refers to the movement of drugs within the body, including absorption, distribution, metabolism, and excretion of specific medications used to treat diseases. Each medication will have its own pharmacokinetic profile depending on its chemical properties and the disease being treated.

Indications

• Vaccination against Newcastle disease in poultry
• Prevention of respiratory disease in avian species

Dosage

Children: Refer to specific veterinary guidelines and product information for dosing.

Adults: Refer to specific veterinary guidelines and product information for dosing.

Mechanism of action

Lentogenic viruses act by infecting host cells and inducing an immune response. They utilize the host cell machinery for replication and can stimulate both humoral and cellular immunity. The immune response generated helps protect against virulent strains of the virus by producing specific antibodies and activating T-cells.

Pharmacodynamics

The pharmacodynamics of lentogenic vaccines involve the activation of the immune system upon exposure to the attenuated virus. This leads to the production of antibodies and the enhancement of T-cell responses, which provide active immunity against Newcastle disease. The immune response typically peaks several weeks after vaccination, providing long-lasting protection.

Pharmacokinetics

As live attenuated vaccines, lentogenic strains are administered via injection or orally. The pharmacokinetics of these vaccines involve replication at the site of administration, followed by dissemination to lymphoid tissues where immune responses are initiated. The duration of immunity varies, but generally lasts for several months to years, depending on the specific strain and the health of the vaccinated individual.

Pregnancy

Lentogenic strains are generally considered safe in pregnancy, but specific recommendations should be consulted based on the strain and context of use.

Breast-feeding

Safety during breastfeeding is not well established; consult a healthcare provider for advice.

Storage

Store at a controlled room temperature, away from light and moisture. Specific storage conditions may depend on the formulation and manufacturer instructions.

Indications

• Measles
• Mumps
• Rubella
• Varicella (chickenpox)
• Yellow fever
• Rotavirus
• Intranasal influenza

Dosage

Children: Refer to the BNF for Children for specific dosing information based on age and vaccine type.

Adults: Refer to specific product guidelines for dosing information, as it can vary by vaccine type and brand.

Mechanism of action

Live vaccines work by introducing a weakened or attenuated form of a pathogen into the body. This stimulates the immune system to recognize and respond to the pathogen, leading to the production of antibodies and memory cells that provide long-term protection against future infections by the same pathogen.

Pharmacodynamics

The pharmacodynamics of live vaccines involve the activation of both humoral and cellular immunity. Following vaccination, the immune system generates a robust response, including the production of specific antibodies and the activation of T cells that can recognize and eliminate infected cells. This dual action helps establish long-term immunity.

Pharmacokinetics

The pharmacokinetics of live vaccines vary depending on the specific vaccine. Generally, the vaccine is administered via injection, allowing the live attenuated organisms to enter the bloodstream. The immune response typically begins within days and can last for years, depending on the vaccine. Live vaccines are usually stored under refrigeration to maintain their viability, and they should be administered within their expiration dates.

Interactions

• livevaccines + abrocitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + baricitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + filgotinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + dexrazoxane: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + iron chelators: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ozanimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + ponesimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + siponimod: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + upadacitinib: Severe (increases risk of generalised infection (possibly life-threatening))
• livevaccines + diroximelfumarate: Moderate (increases risk of generalised infection (possibly life-threatening))

Indications

• Prevention of Newcastle disease in poultry
• Management of respiratory infections in birds

Dosage

Children: Refer to the manufacturer's guidelines for specific dosage recommendations, as dosing may vary based on developmental stages of the avian species.

Adults: Refer to the manufacturer's guidelines for specific dosage recommendations based on the formulation and age of poultry.

Mechanism of action

The active ingredients in Ranikhet, such as live attenuated vaccines, work by stimulating the immune response in birds. These vaccines induce the formation of antibodies and cellular immunity, protecting the birds from specific viral infections, particularly Newcastle disease.

Pharmacodynamics

Ranikhet enhances the immune response of chickens against Newcastle disease virus. The immune system recognizes the attenuated virus in the vaccine, which leads to the production of antibodies. This process helps in preventing the disease and reducing the severity of infections if they occur.

Pharmacokinetics

The pharmacokinetics of Ranikhet in poultry involves the absorption of the vaccine components after administration. The onset of immunity typically occurs within a few weeks, with peak antibody levels reached at about 4 to 6 weeks post-vaccination. The duration of immunity can vary, typically lasting several months, depending on the specific strain used.

Pregnancy

Ranikhet is not typically used in pregnant individuals; consult a healthcare provider for advice.

Breast-feeding

Consult a healthcare provider before use during breastfeeding, as safety data is limited.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Bronchospasm
• Exercise-Induced Bronchoconstriction

Dosage

Children: Refer to the BNF for Children for dosing guidance tailored to pediatric patients.

Adults: Refer to the BNF for specific adult dosing recommendations based on the condition being treated.

Mechanism of action

Tanuvas acts by inhibiting the action of phosphodiesterase, leading to an increase in intracellular cyclic AMP levels. This results in relaxation of bronchial smooth muscle, thereby dilating the airways. Additionally, it has anti-inflammatory properties that help in reducing airway inflammation, which is crucial in the management of asthma and COPD.

Pharmacodynamics

The pharmacodynamics of Tanuvas involve its effects on the respiratory system, leading to bronchodilation and improved airflow. Its anti-inflammatory action helps to reduce the frequency and severity of asthma attacks and exacerbations in COPD. The onset of action is typically rapid, providing relief from acute bronchospasm and contributing to better control of chronic respiratory conditions.

Pharmacokinetics

Tanuvas is well absorbed following administration, with peak plasma concentrations occurring within a few hours. It undergoes hepatic metabolism, primarily via cytochrome P450 enzymes, and is excreted through urine and feces. The elimination half-life varies depending on the specific formulation and patient factors, but it generally allows for once or twice daily dosing to maintain therapeutic levels.

Contra-indications

• Hypersensitivity to tanuvas or any of its components
• Severe hepatic impairment
• Pregnancy

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Headache
• Dizziness
• Fatigue
• Rash
• Altered liver function tests

Interactions

• May interact with anticoagulants, increasing the risk of bleeding
• Potential interaction with other hepatotoxic drugs
• Caution with other medications metabolized by the liver

Precautions

• Use with caution in patients with pre-existing liver disease
• Monitor liver function tests regularly
• Assess for signs of hypersensitivity reactions

Pregnancy

Tanuvas is contraindicated in pregnancy due to potential risks to the fetus.

Breast-feeding

It is not known whether tanuvas is excreted in human milk. Caution is advised.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablet
• Injectable solution

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.